FDA Approves BUTORPHANOL TARTRATE — Apotex Corp.

Pfizer has been denied a ruling on its attempt to block Apotex Corp.'s butorphanol tartrate nasal spray (ANDA075499), just days before the 180-day exclusivity period for the generic was set to expire. This ruling clears the way for Apotex to enter the fields of convulsive status epilepticus and opioid-induced sedation, attracting generic competition that will pressure the net sales of Pfizer's branded Toradol nasal spray.